Successful completion of the final stage of clinical trials paves the way for regulatory approval of the drug.
In the United States, the final phase of clinical trials of an HIV vaccine has been completed, showing extreme effectiveness – 99%. The American research university Emory University announced this on Monday, December 2.
The name of the vaccine is Lenocapovir. It should be given twice a year.
It is indicated that the drug has been tested on hundreds of volunteers of different ages and social groups.
“Tests have shown the ability of the vaccine to stimulate the immune system to produce specific antibodies that block the spread of the virus in the body,” the study results indicate.
As the researchers explained, the vaccine was developed based on mRNA technology, which previously ensured success in the creation of vaccines against COVID-19.
“The new approach used in the development of the vaccine allows it to be adapted to different strains of the virus, which is especially important because of its genetic diversity,” the experts pointed out.
They added that the invented vaccine will be especially useful for people whose conditions do not allow them to take daily oral medication, as well as for those belonging to risk groups.
Today, HIV remains one of the most serious threats to public health. According to the WHO, more than 38 million people worldwide live with this diagnosis.
The World Health Organization (WHO) has approved the Bavarian Nordic monkeypox vaccine for use in young people.
In the United States, a decision will go into effect allowing organ transplants between people with HIV.
New Correspondent.net on Telegram and WhatsApp. Subscribe to our channels Athletistic and WhatsApp
Source: korrespondent
I am Ben Stock, a passionate and experienced digital journalist working in the news industry. At the Buna Times, I write articles covering technology developments and related topics. I strive to provide reliable information that my readers can trust. My research skills are top-notch, as well as my ability to craft engaging stories on timely topics with clarity and accuracy.